The association between excessive alcohol consumption and liver disease is well documented. In fact, the effect on alcohol consumption levels during the COVID-19 pandemic has more recently been investigated. In a 2022 Hepatology article, researchers estimated that the one-year increase in alcohol consumption during the pandemic would result in an …
4 emerging trends to watch in immunotherapy clinical trials
Approaches to systemic anticancer therapy have shifted in recent decades. The nonspecific cytotoxic agents that once dominated the oncotherapy space first gave way to more targeted agents in the 1980s and 1990s, after which advanced, novel immunotherapeutic strategies took center stage. The potential of such immunotherapies to address untreatable malignancies …
snapClinical® team launches eSource module to revolutionize at-home care for Labcorp Drug Development Mobile Clinical Services
This is a special edition of the Labcorp Drug Development Decentralized Clinical Trial (DCT) blog. Labcorp Drug Development Mobile Clinical Services (MCS) team has now completed the first global visit utilizing the eSource module of the proprietary Labcorp DCT platform, snapClinical. This module represents a cross-functional effort to develop a …
Labcorp to open new kit production innovation base in Suzhou, China
In late July, Labcorp joined the signing ceremony of its kit production innovation base project in Suzhou New District, China. The event was held and organized by the Suzhou New District government and saw attendance from city leadership officials, including Deputy Mayor of Suzhou city, Mr. Xiaodong Tang. The Kit …
Labcorp DCT representation at ARCS, Medidata NEXT, DIA and more – July 2022
Welcome to the July 2022 Labcorp Drug Development Decentralized Clinical Trial (DCT) blog. This month, we are going to review our recent presence at several important industry events and provide you with links to a new case study and a just-released video about our snapClinical® technology platform. It has been …
More than a partner: How Labcorp Central Laboratories managed the 65-day Shanghai lockdown
With five global central laboratories, Labcorp understands the value of around-the-clock support to advance clinical trial testing, but the recent 65-day lockdown at their Shanghai facilities gave new meaning to “around the clock.” Understanding the severity of the situation On March 28, 2022, the entire population of Shanghai was suddenly …
Rare Disease Day 2022: Supporting patients, celebrating advancements
February 28 is Rare Disease Day, a day dear to the hearts of many at Labcorp. The day is observed to raise awareness and give support to the more than 300 million people worldwide living with rare diseases, as well as their family members and caretakers. At the heart of …
Cell and Gene Therapy Answers: Advancing treatments for pediatric patients with rare diseases
Your source for answers to the complex challenges of cell and gene therapy development. Labcorp’s cell and gene therapy scientific leaders shared their insights on the factors that make rare and pediatric diseases a good fit for cell and gene therapy, along with the key challenges and best practices in …
Can We Expand Companion Diagnostics Beyond Oncology?
The majority of today’s approved companion (and complementary) diagnostics (CDx) support personalized medicine efforts in oncology, a testament to researchers’ growing knowledge regarding the genetic pathways impacted in various cancers. That understanding increases our ability to convert such knowledge of biology into treatments that specifically target disease based on a …
Finding the Other 90%: Attracting Naïve Patients to RA Studies
A recent study by Tufts Center for the Study of Drug Development, based on a survey of 2,000 physicians and nurses primarily in the United States and Europe, found that 91% of physicians feel ‘somewhat’ or ‘very’ comfortable discussing the opportunity to participate in a clinical trial with patients, but …